CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Aug. 27, 2024--
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two investor conferences in September. Details for the presentations are as follows:
Morgan Stanley 22nd Annual Global Healthcare Conference
Fireside Chat
Date: Thursday, September 5, 2024
Time: 1:05 p.m. Eastern Time
Location: New York, NY
H.C. Wainwright 26th Annual Global Investment Conference
Company Overview
Date: Wednesday, September 11, 2024
Time: 9:00 a.m. Eastern Time
Location: New York, NY
A live webcast of the presentations can be accessed in the Investor section of the Company’s website at https://ir.reparerx.com/news-and-events/events. A replay of the webcast will be archived on the Company’s website for at least 30 days.
About Repare Therapeutics, Inc.
Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes lunresertib (also known as RP-6306), a PKMYT1 inhibitor currently in Phase 1/2 clinical development; camonsertib (also known as RP-3500), a potential leading ATR inhibitor currently in Phase 1/2 clinical development; RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a preclinical Polθ ATPase inhibitor program; as well as additional, undisclosed preclinical programs. For more information, please visit www.reparerx.com and follow @Reparerx on X (formerly Twitter) and LinkedIn.
SNIPRx® is a registered trademark of Repare Therapeutics Inc.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20240827041601/en/
Investor Relations & Media:
Robin Garner
Vice President and Head of Investor Relations
Repare Therapeutics Inc.
investor@reparerx.com
Source: Repare Therapeutics Inc.
